The platform, called Viper, combines deep learning technology with pathology workflows to facilitate patient identification for clinical trials. The software, which aims to facilitate peer-to-peer collaboration and clinical research pathologists, can flag trial-eligible patients at the time of diagnosis.
“With this additional capital, we will move to quickly leverage our successes in the pathology industry and apply a highly disruptive approach to patient identification in clinical trials, one of the most expensive and time intensive issues faced by the pharmaceutical industry,” Deep Lens President and co-founder Simon Arkell said in a news release.
More articles on artificial intelligence:
Vox Media: AI can easily be fooled
American College of Radiology, Nvidia team up to deploy AI in radiology
Berkeley Lab researchers use AI to determine veterans’ suicide risk
